


Erica Pan, MD, MPH
Director and State Public Health Officer

Gavin Newsom
Governor

April 8, 2025

IZB-FY-24-25-08

TO: California Vaccines for Children (VFC) Providers

FROM: Robert Schechter, M.D., Chief, Immunization Branch 
Division of Communicable Disease Control
Center for Infectious Diseases

SUBJECT: 2025 ACIP Child and Adolescent Immunization Schedule

Dear VFC provider:

The **2025 Advisory Committee on Immunization Practices (ACIP) [Child and Adolescent Immunization Schedule](#)** has been released, with full recommendations at [ACIP Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — US, 2025](#).

KEY UPDATES

COVID-19

- One or more doses of updated 2024-25 formula vaccine.
- Additional doses recommended for immunocompromised children.
- Use doses from the same manufacturer for healthy children 6 months - 4 years and immunocompromised individuals receiving initial vaccine series.
- [ACIP COVID-19 Vaccine Recommendations](#)

Hib

- Hexavalent Vaxelis and monovalent PRP-OMP PedvaxHIB are the two preferred vaccines for American Indian/Alaska Native infants.
- [ACIP Haemophilus Influenzae Type B \(Hib\) Vaccine Recommendations](#)

Influenza

- 2024-25 influenza vaccines are trivalent.
- 18-year-old solid organ transplant recipients receiving immunosuppressive medications may receive high-dose inactivated and adjuvanted inactivated vaccines with no preference over other age-appropriate flu vaccines.
- Note: high-dose and adjuvanted influenza vaccines are not available for 2024-25 season but will be for 2025-26 season.
- [ACIP Influenza \(Flu\) Vaccine Recommendations](#).

Meningococcal serogroup B

- New Bexsero dosing interval: two-dose series for healthy adolescents and a three-dose series for those at increased risk of disease.
- Patients who need rapid protection (e.g., outbreak) can choose a three-dose series.
- [ACIP Meningococcal Vaccine Recommendations](#).

CLARIFICATIONS

- **Dengue**
 - Recommended only for seropositive populations 9-16 years in endemic areas.
- **Diphtheria, tetanus, and acellular pertussis-containing (DTaP)**
 - May administer Td for children younger than 7 years with specific contraindication to the pertussis component of DTaP.
- **Inactivated poliovirus (IPV)**
 - Catch-up vaccination is recommended for 18-year-olds known or suspected to be unvaccinated or incompletely vaccinated.
- **Measles, mumps and rubella virus (MMR)**
 - Children at least 12 months of age vaccinated with one dose of MMR and planning international travel should receive a second dose at least four weeks after the first.
- **Measles, mumps, rubella and varicella virus (MMRV)**
 - MMRV vaccine is contraindicated in HIV-infected people.

- **Respiratory syncytial virus (RSV)**
 - Ideal timing of nirsevimab for infants born October through March is during the birth hospitalization.
 - Infants born to people who received RSV vaccine during a previous pregnancy should receive nirsevimab.

REPORTING SUSPECTED VACCINE ADVERSE EVENTS OR ERRORS

Providers should report suspected adverse events to any vaccine to the Vaccine Adverse Events Reporting System (VAERS) at 800-822-7967 (toll-free) or <http://vaers.hhs.gov>.

Providers should report any vaccine administration error and associated contributing factors to the National Vaccine Errors Reporting Program (VERP) at www.ismp.org/form/verp-form. As a part of the report, providers can make recommendations to prevent errors. This surveillance program aims to prevent errors by identifying trends, creating targeted education, and changing product labeling and design.

Health Professionals, consumers, and patients can voluntarily report observed or suspected adverse events for human medical products, such as nirsevimab/Beyfortus™, to FDA through the [MedWatch](#) system.

VFC PROGRAM REQUIREMENTS REMINDER

Per the [VFC Provider Agreement Addendum](#), all active VFC Providers agree to “order all ACIP-recommended vaccines (including flu, COVID-19, RSV and special-order vaccines), and nonroutine vaccines when indicated or requested, to meet the needs of the total VFC-eligible patient populations reported for the provider PIN.” Additionally, VFC Providers agree that for the “vaccines identified and agreed upon in the provider profile ... will comply with immunization schedules, dosages, and contraindications that are established by the ACIP and included in the VFC program unless: a) In the provider's medical judgment, and in accordance with accepted medical practice, the provider deems such compliance to be medically inappropriate for the child; b) The particular requirements contradict state law, including laws pertaining to religious and other exemptions.” Ensure that your practice is ordering and administering vaccines according to ACIP recommendations to protect your patients from vaccine preventable diseases.

ADDITIONAL RESOURCES

- Influenza vaccine resources from [CDC](#) and [CDPH](#)
- COVID-19 vaccine resources from [CDC](#) and [CDPH](#)
- [California Vaccines for Children \(VFC\) \(eziz.org\)](#)
- Meningococcal vaccine timing guides for [routine use](#) and [high risk populations](#). (CDPH)
- [Schedules and Recommendations – California Vaccines for Children \(VFC\)](#)